It is made available under a CC-BY-NC-ND 4.0 International license .

Genetic mechanisms of critical illness in Covid-19

² Erola Pairo-Castineira^{*},¹ Sara Clohisey^{*},¹ Lucija Klaric^{*},² Andrew Bretherick^{*},^{1,2} Konrad Rawlik^{*},¹ Nick
³ Parkinson,¹ Dorota Pasko,³ Susan Walker,³ Anne Richmond,² Max Head Fourman,¹ Clark D Russell,^{1,4}
⁴ Andrew Law,¹ James Furniss,¹ Elvina Gountouna,⁵ Nicola Wrobel,⁶ Loukas Moutsianas,³ Bo Wang,¹
⁵ Alison Meynert,² Zhijian Yang,⁷ Ranran Zhai,⁷ Chenqing Zheng,⁷ Fiona Griffiths,¹ Wilna Oosthuyzen,¹

Graeme Grimes,² Barbara Shih,¹ Sean Keating,⁸ Marie Zechner,¹ Chris Haley,¹ David J. Porteous,⁵ Caroline
 Hayward,⁵ Julian Knight,⁹ Charlotte Summers,¹⁰ Manu Shankar-Hari,^{11,12} Paul Klenerman,⁹ Lance

Turtle,¹³ Antonia Ho,¹⁴ Charles Hinds,¹⁵ Peter Horby,¹⁶ Alistair Nichol,^{17,18,19} David Maslove,²⁰ Lowell
 Ling,²¹ Danny McAuley,^{22,23} Hugh Montgomery,²⁴ Timothy Walsh,⁸ The GenOMICC Investigators, The

⁹ Ling,²¹ Danny McAuley,^{22,23} Hugh Montgomery,²⁴ Timothy Walsh,⁶ The GenOMICC Investigators, The ¹⁰ ISARIC-4C Investigators, The Covid-19 Human Genetics Initiative, Xia Shen,^{7,25,26} Kathy Rowan,²⁷ Angie

¹⁰ ISARIC-4C Investigators, The Covid-19 Human Genetics Initiative, Xia Shen, ^{1,20,20} Kathy Rowan, ²¹ Angle ¹¹ Fawkes, ⁶ Lee Murphy, ⁶ Chris P. Ponting, ² Albert Tenesa, ^{1,2,25} Mark Caulfield, ^{3,15} Richard Scott, ^{3,28} Peter

¹² J.M. Openshaw,²⁹ Malcolm G. Semple.³⁰ Veronique Vitart.² James F. Wilson,^{2,25} J. Kenneth Baillie.^{1,8}

13 Affiliations

- 14 1. Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh,
 Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
- ¹⁷ 3. Genomics England, London, Uk.
- University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh, UK.
- Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
- Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.
- ²⁴ 7. Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
- 8. Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.
- 9. Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
- ²⁸ 10. Department of Medicine, University of Cambridge, Cambridge, UK.
- ²⁹ 11. Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK.
- ³⁰ 12. School of Immunology and Microbial Sciences, King's College London, UK.
- 13. NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection,
 Veterinary and Ecological Sciences University of Liverpool, Liverpool, L69 7BE, UK.
- 14. MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflamma tion, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK.
- 15. William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen
 Mary University of London, London EC1M 6BQ, UK.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford,
 Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.
- 17. Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ire land.
- ⁴¹ 18. Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.
- ⁴² 19. Intensive Care Unit, Alfred Hospital, Melbourne, Australia.

- 20. Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre,
 Kingston, ON, Canada.
- ⁴⁵ 21. Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales
 ⁴⁶ Hospital, Hong Kong, China.
- 47 22. Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern
 48 Ireland, UK.
- 49 23. Department of Intensive Care Medicine, Royal Victoria Hospital, Belfast, Northern Ireland, UK.
- ⁵⁰ 24. UCL Centre for Human Health and Performance, London, W1T 7HA, UK.
- 25. Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics,
 Teviot Place, Edinburgh EH8 9AG, UK.
- ⁵³ 26. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- ⁵⁴ 27. Intensive Care National Audit & Research Centre, London, UK.
- 28. Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
- National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.
- ⁵⁸ 30. University of Liverpool, Liverpool, UK.
- $_{59}$ * Joint first authorship. These authors contributed equally to this work.
- Address for correspondence: Dr J Kenneth Baillie, Roslin Institute, University of Edinburgh, Easter Bush,
 Edinburgh, EH25 9RG, UK.
- 62 email: j.k.baillie@ed.ac.uk

It is made available under a CC-BY-NC-ND 4.0 International license .

63 Abstract

⁶⁴ The subset of patients who develop critical illness in Covid-19 have extensive inflammation affecting the lungs¹

and are strikingly different from other patients: immunosuppressive therapy benefits critically-ill patients, but

⁶⁶ may harm some non-critical cases.² Since susceptibility to life-threatening infections and immune-mediated

⁶⁷ diseases are both strongly heritable traits, we reasoned that host genetic variation may identify mechanistic

 $_{68}$ targets for the rapeutic development in Covid-19.³

⁶⁹ GenOMICC (Genetics Of Mortality In Critical Care, genomicc.org) is a global collaborative study to un-⁷⁰ derstand the genetic basis of critical illness. Here we report the results of a genome-wide association study

 $_{71}~$ (GWAS) in 2244 critically-ill Covid-19 patients from 208 UK intensive care units (ICUs), representing $>\!95\%$

⁷² of all ICU beds. Ancestry-matched controls were drawn from the UK Biobank population study and results

were confirmed in GWAS comparisons with two other population control groups: the 100,000 genomes project
 and Generation Scotland.

⁷⁵ We identify and replicate three novel genome-wide significant associations, at chr19p13.3 (rs2109069, $p = 3.98 \times 10^{-12}$), within the gene encoding dipeptidyl peptidase 9 (*DPP9*), at chr12q24.13 (rs10735079, $p = 1.65 \times 10^{-8}$) in a gene cluster encoding antiviral restriction enzyme activators (*OAS1*, *OAS2*, *OAS3*), and at chr21q22.1 (rs2236757, $p = 4.99 \times 10^{-8}$) in the interferon receptor gene *IFNAR2*. Consistent with our focus on extreme disease in younger patients with less comorbidity, we detect a stronger signal at the known 2×10^{-12} (rs2236757) is a stronger signal at the known focus on extreme disease in younger patients with less comorbidity.

⁸⁰ 3p21.31 locus than previous studies (rs73064425, $p = 4.77 \times 10^{-30}$).

 $_{\mathtt{81}}$ We identify potential targets for repurposing of licensed medications. Using Mendelian randomisation we

 $_{82}$ found evidence in support of a causal link from low expression of *IFNAR2*, and high expression of *TYK2*, to

⁸³ life-threatening disease. Transcriptome-wide association in lung tissue revealed that high expression of the

 $_{84}$ monocyte/macrophage chemotactic receptor CCR2 is associated with severe Covid-19.

Our results identify robust genetic signals relating to key host antiviral defence mechanisms, and mediators of inflammatory organ damage in Covid-19. Both mechanisms may be amenable to targeted treatment with

⁸⁶ of inflammatory organ damage in Covid-19. Both mechanisms may be amenable to targeted treatment with ⁸⁷ existing drugs. Large-scale randomised clinical trials will be essential before any change to clinical practice.

Introduction

Critical illness in Covid-19 is caused, in part, by inflammatory injury affecting the lungs and lung blood 89 vessels.^{4,5} There are therefore at least two distinct biological components to mortality risk: susceptibility to 90 viral infection, and propensity to develop harmful pulmonary inflammation. Susceptibility to life-threatening 91 infections⁶ and immune-mediated diseases are both strongly heritable. In particular, susceptibility to respi-92 ratory viruses⁷ such as influenza⁸ is heritable and known to be associated with specific genetic variants.⁹ In 93 Covid-19, one genetic locus, 3p21.31 has been repeatedly associated with hospitalisation.^{10,11} As with other 94 viral illnesses,¹² there are several examples of loss-of-function variants affecting essential immune processes 95 that lead to severe disease in young people: for example TLR7 defects among 4 cases with severe disease.¹³ 96 Understanding the molecular mechanisms of critical illness in Covid-19 may reveal new therapeutic targets 97 to modulate this host immune response to promote survival.³ 98

⁹⁹ There is now strong evidence that critical illness caused by Covid-19 is qualitatively different from mild ¹⁰⁰ or moderate disease, even among hospitalised patients. There are multiple distinct disease phenotypes with ¹⁰¹ differing patterns of presenting symptoms¹⁴ and marked differential responses to immunosuppressive therapy.² ¹⁰² In patients without respiratory failure, there is a trend towards harm from treatment with corticosteroids, ¹⁰³ whereas among patients with critical respiratory failure, there is a very substantial benefit.² On this basis, ¹⁰⁴ we can consider patients with critical Covid-19 respiratory failure to have distinct pathophysiology.

¹⁰⁵ In the UK, the group of patients admitted to critical care is relatively homogeneous, with profound hypox-¹⁰⁶ aemic respiratory failure being the archetypal presentation.¹⁵ The active disease process in these patients ¹⁰⁷ is strikingly responsive to corticosteroid therapy¹⁶ and is characterised by pulmonary inflammation includ-¹⁰⁸ ing diffuse alveolar damage, macrophage/monocyte influx, mononuclear cell pulmonary artery vasculitis and

¹⁰⁹ microthrombus formation.^{4,5}

It is made available under a CC-BY-NC-ND 4.0 International license .

¹¹⁰ Host-directed therapies have long been an aspiration for the treatment of severe disease caused by respiratory ¹¹¹ viruses.¹⁷ Identification of genetic loci associated with susceptibility to Covid-19 may lead to specific targets

¹¹² for repurposing or drug development.³

The GenOMICC (Genetics Of Mortality In Critical Care, genomicc.org) study has been recruiting patients with critical illness syndromes, including influenza, sepsis, and emerging infections, for 5 years. GenOMICC works in partnership with Genomics England to study Covid-19. In order to better understand the host mechanisms leading to life-threatening Covid-19, we performed a genome-wide association study comparing to controls from population genetic studies in the UK.

118 Results

¹¹⁹ Critically-ill cases were recruited through the GenOMICC study in 208 UK Intensive Care Units and hospi-

talised cases through the International Severe Acute Respiratory Infection Consortium (ISARIC) Coronavirus

¹²¹ Clinical Characterisation Consortium (4C) study. Demographic and summary clinical characteristics of the

¹²² cohort are described in Table 1. Cases were representative of the UK critically-ill population.¹⁵

Table 1: Baseline characteristics of patients included. Significant comorbidity was defined as the presence of functionally-limiting comorbid illness in GenOMICC, in the assessment of the treating clinicians. In ISARIC 4C significant comorbidity refers to the presence of any chronic cardiac, lung, kidney, or liver disease, cancer or dementia. Age is shown as mean \pm standard deviation.

Patient Characteristics	GenOMICC $(n=2109)$		ISARIC 4C $(n=134)$	
		missing data		missing data
Female sex	624 (30%)	-	46 (34%)	-
Age (yrs, mean \pm SD)	57.3 ± 12.1		57.3 ± 2.9	
European ancestry	1573~(75%)		103~(76%)	
South Asian ancestry	219 (10%)		18 (13%)	
African ancestry	174 (8%)		8 (6%)	
East Asian ancestry	143 (7%)		6(4%)	
Significant comorbidity	396 (19%)	49(2%)	42 (28%)	31 (21%)
Invasive ventilation	1557 (74%)	35(2%)	25(19%)	31(23%)
Died (60 days)	459(22%)	338~(16%)	22~(16%)	30~(22%)

DNA was extracted from whole blood and genome-wide genotyping and quality control were performed 123 according to standard protocols (Materials & Methods). Briefly, genetic ancestry was inferred for unrelated 124 individuals passing quality control using ADMIXTURE and reference individuals from the 1000 Genomes 125 project. Imputation was performed using the TOPMed reference panel.¹⁸ Whole genome sequencing was 126 performed on a subset of 1613 cases, and used to confirm both array-genotyped and imputed genotypes. 127 From the 4469187 imputed variants that passed all filters after GWAS, 72658 did not pass QC filtering in 128 WGS data and were removed. Comparing the allele frequencies of each SNP between WGS and imputation, 129 the correlation of allele frequencies was $r^2 = 0.9994$. All variants with a difference of > 5% were removed from 130 the analysis, leaving 4396207 imputed variants. 131

Ancestry-matched controls not having Covid-19 PCR tests were selected from the large population-based 132 cohort UK Biobank in a ratio of 5 controls to 1 case. GWAS was carried out separately by ancestry group 133 using logistic regression in PLINK and accounting for age, sex, postal code deprivation decile and principal 134 components of ancestry. As well as standard filters for minor allele frequency (>0.01), imputation quality 135 (0.9) and Hardy-Weinberg equilibrium $(10^{-}50^{-})$, GWAS results were filtered on allele frequency against the 136 genome aggregation database (gnomAD), to avoid biases arising from different imputation panels (and arrays) 137 between cases and controls. The largest ancestry group contained 1676 individuals of European descent 138 (EUR). 139

¹⁴⁰ Following linkage disequilibrium-based clumping, 15 independent association signals were genome-wide sig-

¹⁴¹ nificant at $p < 5 \times 10^{-8}$. Eight of these were successfully validated using a GWAS using two independent ¹⁴² population genetic studies (100,000 genomes and Generation Scotland) as controls (Table 2).



Figure 1: Summary of GWAS results for EUR ancestry group in GenOMICC. *a.* Manhattan plot showing SNP-level p-values for genome-wide significant associations in largest ancestry group, EUR (red horizontal line shows genome-wide significance at $-log_{10}(5x10^{-8})$) *b-d.* Locuszoom¹⁹ plots showing genomic regions around protein-coding genes. *e.* Quantile-quantile (QQ) plot.

143 GWAS results

Table 2: Lead variants from independent genome-wide significant regions. Full summary statistics are provided in Supplementary Information. chr:pos - chromosome and position of the top SNP (build 37); Risk – risk allele; Other - other allele; RAF - risk allele frequency; OR - effect size (odds ratio) of the risk allele; locus – gene nearest to the top SNP.

SNP	$\operatorname{chr:pos}(b37)$	Risk	Other	RAF	OR	Р	Locus
rs73064425	3:45901089	Т	\mathbf{C}	0.08	2.14	$4.77 \ge 10^{-30}$	LZTFL1
rs9380142	6:29798794	А	G	0.70	1.30	$3.23 \ge 10^{-8}$	HLA- G
rs143334143	6:31121426	Α	G	0.079	1.85	$8.82 \ge 10^{-18}$	CCHCR1

It is made available under a CC-BY-NC-ND 4.0 International license .

SNP	$\operatorname{chr:pos}(\mathrm{b37})$	Risk	Other	RAF	OR	Р	Locus
rs3131294	6:32180146	G	А	0.87	1.45	$2.81 \ge 10^{-8}$	NOTCH4
rs10735079	12:113380008	Α	G	0.64	1.29	$1.65 \ge 10^{-8}$	OAS3
rs74956615	19:10427721	Α	Т	0.06	1.59	$2.31 \ge 10^{-8}$	ICAM5/TYK2
rs2109069	19:4719443	Α	G	0.33	1.36	$3.98 \ge 10^{-12}$	DPP9
rs2236757	21:34624917	А	G	0.29	1.28	$5.00 \ge 10^{-8}$	IFNAR2

Since no study of critical illness in Covid-19 of sufficient size is available, replication was sought in the Covid-19 Host Genetics Initiative (HGI) hospitalised COVID-19 versus population analysis, with UK Biobank cases excluded. In addition to the locus on chr3 already reported (rs73064425, OR=2.14, discovery p=4.77 × 10^{-30}), we found robust replication for the novel associations in three loci from GenOMICC: a locus on chr12 in the OAS gene cluster (rs74956615, OR=1.59, discovery p=1.65 × 10⁻⁸) and in DPP9 on chr19 (rs2109069, OR=1.36, discovery p=3.98 × 10⁻¹²) and locus on chromosome 21, containing gene IFNAR2 (rs2236757, OR=1.28, p=5 × 10⁻⁸) (Table 3).

151 Replication

Table 3: Replication in external data from Covid-19 HGI. chr:pos - chromosome and position of the top SNP (build 37); Risk – risk allele; Other - other allele; beta - effect size of the risk allele; OR - odds ratio; locus – gene nearest to the top SNP; gcc.eur - GenOMICC study, European ancestry; hgi - Covid-19 human genetics initiative; * Bonferroni significant.

SNP	chr:pos $(b37)$	Risk	Other	beta gcc.eur	P gcc.eur	beta hgi	P hgi	Locus
rs73064425	3:45901089	Т	С	0.76	4.8 x 10 ⁻³⁰	0.53	$1.6 \ge 10^{-12*}$	LZTFL1
rs9380142	6:29798794	Α	G	0.26	$3.2 \ge 10^{-8}$	0.036	0.46	HLA- G
rs143334143	6:31121426	А	G	0.62	$8.8 \ge 10^{-18}$	0.064	0.34	CCHCR1
rs3131294	6:32180146	G	А	0.38	$2.8 \ge 10^{-8}$	0.1	0.2	NOTCH4
rs10735079	12:113380008	А	G	0.26	$1.6 \ge 10^{-8}$	0.14	0.0027^{*}	OAS3
rs2109069	19:4719443	Α	G	0.31	$4 \ge 10^{-12}$	0.17	0.00031^{*}	DPP9
rs74956615	19:10427721	А	Т	0.46	$2.3 \ge 10^{-8}$	0.14	0.4	ICAM5/TYK2
rs2236757	21:34624917	А	G	0.25	$5\ge 10^{-8}$	0.18	0.00016^{*}	IFNAR2

¹⁵² To further increase power for exploratory downstream analyses meta-analysis of GENOMICC and HGI was

performed using inverse-variance meta-analysis in METAL,²⁰ discovering 2 additional loci, one on chromosome 8, near *HAS2* (rs10087754, OR=1.19, meta-analysis $p = 3.1 \times 10^{-8}$) and another on chromosome 19,

¹⁵⁵ near *TYK2* (rs11085727, OR=1.25, $p = 1.57 \times 10^{-10}$) (Table 4).

Table 4: Meta-analysis of GenOMICC (EUR) and HGI hospitalized covid vs. population studies. SNP – the strongest SNP in the locus, ; A1 – effect allele; A2 - alternative allele; beta - effect size of the effect allele; nearest gene – gene nearest to the top SNP.

SNP	A1	A2	beta eur	p eur	beta hgi.meta	OR hgi.meta	p hgi.meta	Gene
rs67959919	А	G	0.76	7.1 x 10 ⁻³⁰	0.66	1.9	7.3 x 10 ⁻³⁸	LZTFL1
rs143334143	Α	G	0.62	$8.8 \ge 10^{-18}$	0.31	1.4	$7 \ge 10^{-10}$	CCHCR1
rs9501257	G	А	0.49	$1.1 \ge 10^{-11}$	0.31	1.4	$3.8 \ge 10^{-9}$	HLA-DPB1
rs622568	\mathbf{C}	А	0.45	$7.1 \ge 10^{-16}$	0.29	1.3	$7 \ge 10^{-11}$	VSTM2A
rs10087754	Т	А	0.19	$7.6 \ge 10^{-6}$	0.18	1.2	$3.1 \ge 10^{-8}$	HAS2-ASI
rs10860891	\mathbf{C}	А	0.55	$1.6 \ge 10^{-18}$	0.3	1.3	$7.5 \ge 10^{-10}$	IGF1
rs4766664	G	Т	0.25	$3.1 \ge 10^{-8}$	0.2	1.2	$2.5 \ge 10^{-9}$	OAS1
rs2277732	Α	\mathbf{C}	0.3	$1.8 \ge 10^{-11}$	0.25	1.3	$1.6 \ge 10^{-13}$	DPP9

It is made available under a CC-BY-NC-ND 4.0 International license .

SNP	A1	A2	beta eur	p eur	beta hgi.meta	OR hgi.meta	p hgi.meta	Gene
rs11085727	Т	С	0.24	$1.3 \ge 10^{-7}$	0.22	1.2	$1.6 \ge 10^{-10}$	TYK2
rs13050728	Т	\mathbf{C}	0.23	$3 \ge 10^{-7}$	0.21	1.2	$2.5 \ge 10^{-10}$	IFNAR2

156 Mendelian randomisation

¹⁵⁷ Mendelian randomisation provides evidence for a causal relationship between an exposure variable and an ¹⁵⁸ outcome, given a set of assumptions.²¹ We employ it here to assess the evidence in support of causal effects ¹⁵⁹ of RNA expression of various genes on the odds of critical Covid-19.

We specified an *a priori* list of target genes that relate to the mechanism of action of many host-targeted drugs that have been proposed for the treatment of Covid-19 (Supp Table 1). Seven of these targets had a suitable locally-acting eQTL in GTEx(v7). Of these, *IFNAR2* remained significant after Bonferroni correcting for multiple testing for 7 tests (beta -1.49, standard error 0.52, p-value 0.0043), with equivocal evidence of heterogeneity (HEIDI²² p-value = 0.0150; 0.05/7 < p-value < 0.05; 6 SNPs). This Mendelian randomisation result successfully replicated in the results of COVID19-hg (ANA_B2_V2; hospitalized covid vs. population; UK Biobank excluded): beta -1.37, standard error 0.51, p-value 0.0066 (1 test).

We then performed transcriptome-wide Mendelian randomisation to quantify support for *unselected* genes 167 as potential therapeutic targets. Instruments were available for 4.614 unique Ensembl gene IDs. No genes 168 were statistically significant after correcting for multiple comparisons in this analysis (4,614 tests). After 169 conservative filtering for heterogeneity (HEIDI p-value > 0.05), the smallest Mendelian randomisation p-170 value was 0.00049 for a variant at chr19:10466123 affecting expression of TYK2. 9 other genes with nominally 171 significant Mendelian randomisation pvalues (p < 0.005) were then tested for independent external evidence 172 (Supplementary Information). We found that TYK2 had a significant independent Mendelian randomisation 173 p = 0.0022 in this second set (Bonferroni-corrected significance threshold = 0.006). In both cases it should 174 be noted that this is not a complete replication, because the same GTEx expression data was used for both 175 analyses. 176

$_{177}$ TWAS

We performed TWAS^{23,24} to link GWAS results to tissue-specific gene expression data by inferring gene expression from known genetic variants that are associated with transcript abundance (expression quantitative trait loci, eQTL). For this analysis we used GTExv8 data for two disease-relevant tissues chosen *a priori*: whole blood and lung(Figure 3), and performed a combined meta-TWAS analysis²⁵ to detect predicted expression differences across both tissues.

We discovered 18 genes with genome-wide significant differences in predicted expression compared to controls (Supplementary Information). This included 4 genes with differential predicted expression in lung tissue (Figure 3; 3 on chr3: *CCR2*, *CCR3* and *CXCR6*, and 1 on chr5: *MTA2B*).

¹⁸⁶ Genetic correlations, tissue, and cell-type associations

We tested for genetic correlations with other traits, that is the degree to which the underlying genetic components are shared with severe Covid-19. Using the high-definition likelihood (HDL) method,²⁶ we identified significant negative genetic correlations with educational attainment and intelligence. Significant positive genetic correlations were detected for a number of adiposity phenotypes including body mass index and leg fat, as well as pulse rate, neck/shoulder pain, thyroxine, and lansoprazole medications.

¹⁹² Consistent with GWAS results from other infectious and inflammatory diseases,²⁷ there was a significant ¹⁹³ enrichment of strongly-associated variants in promoters and enhancers, particularly those identified by the ¹⁹⁴ EXaC study as under strong evolutionary selection (Supplementary Information).²⁸ The strongest tissue type

¹⁹⁵ enrichment was in spleen, followed by pancreas (Supplementary Information).

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 2: Detail of the TYK2 and IFNAR2 loci showing location of instrumental variables used for Mendelian randomisation. x-axes: genomic position with gene locations marked; y-axes: GenOMICC GWAS -log10(p-values); dashed line: genome-wide significance at $-log_{10}(5x10^{-8})$; blue triangles: variants used as the instrumental variables for MR, for TYK2 and IFNAR2, respectively. A detailed description of the method of instrument selection is provided in Materials and Methods.



Figure 3: Summary of TWAS results. *a.* Gene-level Manhattan plot showing results from meta-TWAS analysis across tissues. *b.* z-scores showing direction of effect for genotype-inferred expression of transcripts encoding protein-coding genes in lung tissue (GTEXv8). Red highlighting indicates genome-wide significance at $p < 5 \times 10^{-6}$.

It is made available under a CC-BY-NC-ND 4.0 International license .

Discussion 196

We have discovered and replicated significant genetic associations with life-threatening Covid-19 (Figure 1). 197

Our focus on critical illness increases the probability that some of these associations relate to the later. 198

immune-mediated disease associated with respiratory failure requiring invasive mechanical ventilation.² Im-199

portantly, the GWAS approach is unbiased and genome-wide, enabling the discovery of completely new patho-200

physiological mechanisms. Because genetic variation can be used to draw a causal inference, genetic evidence 201

in support of a therapeutic target substantially improves the probability of successful drug development.²⁹ 202 In particular, Mendelian randomisation occupies a unque position in the hierarchy of clinical evidence.³⁰

203

Patients admitted to intensive care units in the UK during the first wave of Covid-19 were, on average, younger 204 and less burdened by comorbid illness than the hospitalised population.¹⁵ Compared to other countries, UK 205 ICU admission tends to occur at a higher level of illness severity,³¹ reflected in the high rate of invasive 206 mechanical ventilation use in our cohort (73%; Table 1). Therefore, the population studied here are defined 207 by their propensity to critical respiratory failure due to Covid-19. GenOMICC recruited in 208 intensive 208 care units (covering more than 95% of UK ICU capacity), ensuring that a broad spread across the genetic 209 ancestry of UK patients was included (Supplementary Information). 210

For external replication, the nearest comparison is the hospitalised vs population analysis in the Covid-19 211 Host Genetics initiative, which has been generously shared with the international community. Likewise, full 212 summary statistics from GenOMICC are openly available in order to advance the rate of discovery. 213

Despite the differences in case definitions, novel associations from our study of critical illness replicate robustly 214

in the hospitalised case study (Table 3). Separately, the Mendelian randomisation results implying a causal 215

role for IFNAR2 and TYK2 are also statistically significant in this cohort. Our findings reveal that critical 216

illness in Covid-19 is related to at two biological mechanisms: innate antiviral defences, which are known to 217

be important early in disease (IFNAR2 and OAS genes), and host-driven inflammatory lung injury, which is 218

a key mechanism of late, life-threatening Covid-19 (DPP9, TYK2 and CCR2).² 219

Interferons are canonical host antiviral signalling mediators, and stimulate release of many essential compo-220 nents of the early host response to viral infection.³² Consistent with a beneficial role for type I interferons, 221 increased expression of the interferon receptor subunit IFNAR2 reduced the odds of severe Covid-19 with 222 Mendelian randomisation discovery p = 0.0043 (7 tests); replication p = 0.0066 (1 test). Within the assump-223 tions of Mendelian randomisation, this represents evidence for a protective role for IFNAR2 in Covid-19. We 224 deemed this gene to be therapeutically-informative a priori because it is a target for exogenous interferon 225 treatment, with fatal sequelae from live-attenuated measles virus in humans^{33,34} and with influenza in mice.³⁵ 226

The variant rs10735079 (chr12, $p = 1.65 \times 10^{-8}$) lies in the oligoaden value synthetase (OAS) gene clus-227 ter (OAS1, OAS2 and OAS3; Figure 1). TWAS also (Figure 3) detects significant associations in these 228 genes (Figure 3). OAS genes are inducible by type I interferons. These genes encode enzymes which acti-229 vate an effector enzyme, RNAse L, which degrades double-stranded RNA,³⁶ a replication intermediate of 230 coronaviruses.³⁷ OAS1 variants were implicated in susceptibility to SARS-CoV in candidate gene association 231 studies in Vietnam³⁸ and China.³⁹ 232

The association in 19p13.3 (rs2109069, $p = 3.98 \times 10^{12}$) is an intronic variant in the gene encoding dipeptidyl 233 peptidase 9 (DPP9). Variants in this locus are associated with idiopathic pulmonary fibrosis⁴⁰ and interstitial 234 lung disease.⁴¹ DPP9 encodes a serine protease with diverse intracellular functions, including cleavage of the 235 key antiviral signalling mediator CXCL10.⁴² and plays a key role in antigen presentation.⁴³ 236

Since opportunities for the apeutic intervention, particularly experimental therapy, are more abundant in 237 later, more severe disease, it is important that our results also reveal genes that may act to drive inflammatory 238 organ injury. TYK2 is one of 4 gene products listed in the druggable genome Targets Central Resource 239 Database⁴⁴ as a target for baricitinib, one of the nine candidate drugs we used in the creation of our a240 priori target list (Supplementary Table 1). However, since we did not a priori include TYK2 on the final 241 set of genes for focused Mendelian randomisation, we use a significance threshold corrected for the full set of 242 comparisons: discovery p = 0.00049 (4614 tests); replication p = 0.0022 (9 tests). 243

We replicate the finding of Ellinghaus *et al.* at 3p21.31.¹¹ The extremely small p-value at this locus (p=4.77) 244

It is made available under a CC-BY-NC-ND 4.0 International license .

 $\times 10^{-30}$) may reflect the strength of the signal, the large size of our study, our focus on extreme severity. The 3p21.31 locus is populated by a number of genes with mechanisms of action that could plausibly explain an association. Our systematic review and meta-analysis of experimental data on betacoronavirus infection from other sources provides moderate biological support for *FYCO1*, although the additional information comes mostly from *in vitro* model systems.⁴⁵

TWAS results show that variants in this region confer genome-wide significant differences in predicted ex-250 pression of CXCR6, CCR2 and CCR3 (Supplementary Information). Association with critical illness for 251 genotype-inferred CCR2 (CC-chemokine receptor 2) expression is particularly strong in lung tissue(Figure 3). 252 CCR2 promotes monocyte/macrophage chemotaxis towards sites of inflammation, and there is increased ex-253 pression of the canonical ligand for CCR2, monocyte chemoattractant protein (MCP-1), in bronchoalveolar 254 lavage fluid from the lungs of Covid-19 patients during mechanical ventilation.⁴⁶ Circulating MCP-1 concen-255 trations are associated with more severe disease.⁴⁷ Anti-CCR2 monoclonal antibody therapy in treatment of 256 rheumatoid arthritis is safe.⁴⁸ 257

The ABO locus was also previously associated with Covid-19,¹¹ but was not significant in our study (smallest $p=1.30 \times 10^{-3}$, chr9:136115876; Supplementary Information). This does not rule out the possibility of a true association, but other possible explanations include differences between case and control populations in each study.

Analysis of shared heritability highlights adiposity and educational attainment: genetically increased body mass index (BMI) and genetically decreased educational attainment are both associated with higher risk of severe Covid. This does not imply a causal relationship, as a number of biases may be at play, but may reflect the fact that increased BMI and lower socio-economic status are strong risk factors for Covid-19,^{49,50} or the fact that UK Biobank participants were disproportionately drawn from a high socio-economic status group.⁵¹

There is an urgent need to deepen these findings through further studies of this type, with harmonised 268 integration across multiple studies. We continue to recruit to the GenOMICC study, in the expectation that 269 additional associations exist and can be detected with larger numbers of cases. Future studies using whole 270 genome sequencing will add spatial resolution on the genome and better detection rare variants. Effect sizes 271 are likely to be higher in GenOMICC because the cohort is strongly enriched for immediately life-threatening 272 disease in patients who are either receiving invasive mechanical ventilation, or considered by the treating 273 physicians to be at high risk of requiring mechanical support. With 2244 cases we have statistical power 274 to detect strong effects, such as the highly-significant locus at 3p21.31, as well as moderate genome-wide 275 significant findings with external replication at DPP9, OAS and IFNAR2. 276

Because of the urgency of completing and reporting this work, we have drawn controls from population genetic studies who were genotyped using different technology from the cases. We mitigated the consequent risk of false-positive associations driven by genotyping errors by genotyping the majority of our subjects using two different methods, and by verifying significant associations using two separate control groups (100,000 genomes and Generation Scotland). The success of these mitigations is demonstrated by robust replication of our top hits in external studies.

We have discovered new and highly plausible genetic associations with critical illness in Covid-19. Some of these associations lead directly to potential therapeutic approaches to augment interferon signalling, antagonise monocyte activation and infiltration into the lungs, or specifically target harmful inflammatory pathways. While this adds substantially to the biological rationale underpinning specific therapeutic approaches, each

treatment must be tested in large-scale clinical trials before entering clinical practice.

It is made available under a CC-BY-NC-ND 4.0 International license .

²⁸⁸ Materials and methods

289 Recruitment

2,636 patients recruited to the GenOMICC study (genomicc.org) had confirmed Covid-19 according to local 290 clinical testing and were deemed, in the view of the treating clinician, to require continuous cardiorespiratory 291 monitoring. In UK practice this kind of monitoring is undertaken in high-dependency or intensive care 292 units. An additional 134 patients were recruited through ISARIC 4C (isaric4c.net) - these individuals had 293 confirmed Covid-19 according to local clinical testing and were deemed to require hospital admission. Both 294 studies were approved by the appropriate research ethics committees (Scotland 15/SS/0110, England, Wales 295 and Northern Ireland: 19/WM/0247). Current and previous versions of the study protocol are available at 296 genomicc.org/protocol. 297

²⁹⁸ Genotyping

²⁹⁹ DNA was extracted from whole blood using Nucleon Kit (Cytiva) with the BACC3 protocol. DNA samples ³⁰⁰ were re-suspended in 1 ml TE buffer pH 7.5 (10mM Tris-Cl pH 7.5, 1mM EDTA pH 8.0). The yield of the ³⁰¹ DNA was measured using Qubit and normalised to $50 \text{ng}/\mu$ l before genotyping.

Genotyping was performed using the Illumina Global Screening Array v3.0 + multi-disease beadchips (GSAMD-24v3-0-EA) and Infinium chemistry. In summary this consists of three steps: (1) whole genome amplification, (2) fragmentation followed by hybridisation, and (3) single-base extension and staining. For each of the samples, 4 μ l of DNA normalised to 50ng/ μ l was used. Each sample was interrogated on the arrays against 730,059 SNPs. The Arrays were imaged on an Illumina iScan platform and genotypes were called automatically using GenomeStudio Analysis software v2.0.3, GSAMD-24v3-0-EA_20034606_A1.bpm manifest and cluster file provided by manufacturer.

In 1667 cases, genotypes and imputed variants were confirmed with Illumina NovaSeq 6000 whole genome sequencing. Samples were aligned to the human reference genome hg38 and variant called to GVCF stage on the DRAGEN pipeline (software v01.011.269.3.2.22, hardware v01.011.269) at Genomics England. Variants were genotyped with the GATK GenotypeGVCFs tool v4.1.8.1,⁵² filtered to minimum depth 8X (95% sensitivity for heterozygous variant detection,⁵³) merged and annotated with allele frequency with bcftools v1.10.2.

315 Quality control

Genotype calls were carefully examined within GenomeStudio using manufacturer and published⁵⁴ recom-316 mendations, after excluding samples with low initial call rate (<90%) and reclustering the data thereafter. 317 Briefly, X and Y markers calls were all visually inspected and curated if necessary, as were those for au-318 to somal markers with minor allele frequency > 1% displaying low Gentrain score, cluster separation, and 319 excess or deficit of heterozygous calls. Genotype-based sex determination was performed in GenomeStudio 320 and samples excluded if not matching records expectation. Five individuals with XXY genotypes were also 321 detected and excluded for downstream GWAS analyses. Genotypes were exported, in genome reference con-322 sortium human build 37 (GRCHb37) and Illumina "source" strand orientation, using the GenotypeStudio 323 plink-input-report-plugin-v2-1-4. A series of filtering steps was then applied using PLINK 1.9 leaving 324 2799 individuals and 479095 variants for further analyses (exclusion of samples with call rate < 95%, selection 325 of variants with call rate > 99% and minor allele frequency (MAF) > 1% and final samples selection using 326 a call rate > 97%). 327

328 Kinship

³²⁹ Kinship and ancestry inference were calculated following UK Biobank⁵¹ and 1M veteran program.⁵⁵ First King

³³⁰ 2.1⁵⁶ was used to find duplicated individuals which have been recruited by two different routes. The analysis ³³¹ flagged 56 duplicated pairs, from which one was removed according to genotyping quality (GenomeStudio

p50GC score or/and individual call rate). This leaves a set of 2734 unique individuals.

It is made available under a CC-BY-NC-ND 4.0 International license .

Regions of high linkage disquilibrium (LD) defined in the UK Biobank⁵¹ were excluded from the analy-333 sis, as well as SNPs with MAF<1% or missingness >1%. King 2.1 was used to construct a relation-334 ship matrix up to 3rd degree using the King command --kinship --degree 3 and then the function 335 largest_independent_vertex_set() from the igraph tool[[http://igraph.sf.net]] was used to create a first 336 set of unrelated individuals. Principal component analysis (PCA) was conducted with gcta 1.9^{57} in the set 337 of unrelated individuals with pruned SNPs using a window of 1000 markers, a step size of 80 markers and an 338 r^2 threshold of 0.1. SNPs with large weights in PC1, PC2 or PC3 were removed, keeping at least 2/3 of the 339 number of pruned SNPs to keep as an input of the next round of King 2.1. The second round of King 2.1 was 340 run using the SNPs with low weights in PC1, PC2 and PC3 to avoid overestimating kinship in non-european 341 individuals. After this round 2718 individuals were considered unrelated up to 3rd degree. 342

343 Genetic ancestry

Unrelated individuals from the 1000 Genome Project dataset were calculated using the same procedure 344 described above, and both datasets were merged using the common SNPs. The merged genotyped data 345 was pruned with plink using a window of 1000 markers a step size of 50 and a r^2 of 0.05, leaving 92K 346 markers that were used to calculate the 20 first principal components with gcta 1.9. Ancestry for genomicc 347 individuals was inferred using ADMIXTURE⁵⁸ populations defined in 1000 genomes. When one individual 348 had a probability > 80% of pertaining to one ancestry, then the individual was assigned to this ancestry, 349 otherwise the individual was assigned to admix ancestry as in the 1M veteran cohort.⁵⁵ According to this 350 criterion there are 1818 individuals from European ancestry, 190 from African ancestry, 158 from East Asian 351 ancestry, 254 from South Asian ancestry, and 301 individuals with admixed ancestry (2 or more). 352

353 Imputation

Genotype files were converted to plus strand and SNPs with Hardy-Weinberg Equilibrium (HWE) pvalue< 10^{-6} were removed. Imputation was calculated using the TOPMed reference panel.¹⁸ and results were given in grch38 human reference genome and plus strand. The imputed dataset was filtered for monogenic and low imputation quality score ($r^2 < 0.4$) using BCFtools 1.9. To perform GWAS, files in VCF format were further filtered for $r^2 > 0.9$ and converted to BGEN format using QCtools 1.3.⁵⁹

³⁵⁹ UK Biobank imputed variants with imputation score >0.9 and overlapping our set of variants (n=5,981,137)³⁶⁰ were extracted and merged with GenOMICC data into a single BGEN file containing cases and controls using ³⁶¹ QCtools 1.3.

362 GWAS

Individuals with a positive Covid-19 test or suspected Covid-19 when they were admitted in the hospital were included in the GWAS as cases. Related individuals to degree 3 were removed. 13 individuals with American ancestry were removed as the sample size provided insufficient power to perform a reliable GWAS for this group. The final dataset includes 2244 individuals: 1676 individuals from European ancestry, 149 individuals from East Asian ancestry, 237 individuals from South Asian ancestry and 182 individuals from African ancestry (Table 1). If age or deprivation status were missing for some individuals, the value was set to the mean of their ancestry. GWAS were performed separately for each ancestry group.

Tests for association between case-control status and allele dosage at individuals SNPs were performed by

³⁷¹ fitting logistic regression models using PLINK.⁶⁰ Independent analyses were performed for each ethnic group.

All models included sex, age, mean centered age squared, deprivation score decile of residential postcode, and

the first 10 genomic principal components as covariates.

 $_{374}$ Genomic principal components were computed on the combined sample of all UK Biobank and GenOMICC

participants. Specifically, 456,750 genetic variants were identified which were shared between the variants

³⁷⁶ contained in the called genotypes in the GenOMICC dataset and imputed UK Biobank genotypes, which

had an information score above 0.95 and a minor allele frequency above 1%. After merging genotypes at

these variants, variants were removed which had a minor allele frequency below 2.5%, a missingness rate 1.5% at a missingness rat

 $_{379}$ above 1.5%, showed departure from Hardy-Weinberg equilibrium with a p value below 10^{-50} , or which were

It is made available under a CC-BY-NC-ND 4.0 International license .

within previously identified regions of high linkage disequilibrium within UK Biobank. After LD-pruning of the remaining variants to a maximum r² of 0.01 based on a 1000 variant window moving in 50 variants steps, using the PLINK indep-pairwise command and yielding 13,782 SNPs, the leading 20 genomic principal components were computed using FlashPCA2.⁶¹

GWAS results were filtered for MAF>0.01, variant genotyping rate > 0.99 and HWE p-value > 10^{-50} for each 384 ethnicity. An extra filter was added to avoid bias for using a different genotyping method and imputation 385 panel between controls and cases. This could not be controlled for using regression because all cases and 386 all controls were genotyped using different methods. MAF for each ancestry were compared between UK 387 Biobank and gnomAD hg38 downloaded in August 2020.⁶² SNPs were were removed from the GWAS results 388 specifically for each ethnicity following these two rules: (a) In SNPs with MAF > 10% in gnomAD, an absolute 389 difference of 5% between gnomAD and UK biobank controls MAF (b) In SNPs with MAF <10% in gnomAD. 390 a difference > 25% gnomAD MAF, between UK Biobank controls and gnomAD. To calculate differences 391 between UK Biobank European individuals and gnomAD allele frequencies, non Finnish-europeans gnomAD 392 allele frequencues were used, as European UK Biobank controls are mainly non-Finnish. 393

Deprivation score The UK Data Service provides measures of deprivation based on Census Data and generated per postcode. The latest version of the Deprivation Scores were published in 2017 and are based on the 2011 census. Since only partial postcodes were available for most samples we were unable to use these indices directly. However, we generated an approximation to the scores by calculating an average weighted by population count across the top-level postcode areas.

The initial input file was part of the aggregated census data identified by DOI:10.5257/census/aggregate-2011-2.

⁴⁰¹ Specifically the postcode data were downloaded from:

http://s3-eu-west-1.amazonaws.com/statistics.digitalresources.jisc.ac.uk/dkan/files/Postcode_Counts_and
 _Deprivation_Ranks/postcodes.zip

⁴⁰⁴ Population count and deprivation score for each published postcode were extracted and weighted average
 ⁴⁰⁵ score calculated for each top-level postcode. We further categorised each top-level postcode score into decile
 ⁴⁰⁶ and quintile bins for more coarse-grained analyses.

407 Whole Genome Sequencing

Whole Genome Sequencing (WGS) gVCF files were obtained for the 1667 individuals for which we had whole genome sequence data. Variants overlapping the positions of the imputed variants were called using GATk and variants with depth<8 (the minimum depth for which 95% coverage can be expected) were filtered. Individual VCF files were joined in a multi-sample VCF file for comparison with imputed variants. 1613 of these 1667 were used in the final GWAS. Samples were filtered and variants annotaed using bcftools 1.9. VCF files obtained from imputation were processed in an identical manner. Alternative allele frequency was calculated with PLINK 2.0⁶³ for both WGS and imputed data.

415 Controls

416 UK Biobank

UK Biobank participants were were considered as potential controls if they were not identified by the UK 417 Biobank as outliers based on either genotyping missingness rate or heterogeneity, and their sex inferred from 418 the genotypes matched their self-reported sex. For these individuals, information on sex (UKBID 31), age, 419 ancestry, and residential postcode deprivation score decile was computed. Specifically, age was computed 420 as age on April 1st, 2020 based on the participant's birth month (UKBID 34) and year (UKBID 52). The 421 first part of the residential postcode of participants was computed based on the participant's home location 422 (UKBID 22702 and 22704) and mapped to a deprivation score decile as previously described for GenOMICC 423 participants. Ancestry was inferred as previously described for GenOMICC participants. 424

It is made available under a CC-BY-NC-ND 4.0 International license .

425 After excluding participants who had received PCR tests for Covid-19, based on information downloaded

⁴²⁶ from the UK Biobank in August 2020, five individuals with matching inferred ancestry were sampled for each ⁴²⁷ GenOMICC participant as controls. After sampling each control, individuals related up to 3rd degree were

⁴²⁸ removed from the pool of potential further controls.

429 Generation Scotland

Scottish Family Health Study (hereafter referred to as Generation Scotland) Generation Scotland: 430 is a population-based cohort of 24 084 participants sampled from five regional centers across Scot-431 land(www.generationscotland.org).⁶⁴ A large subset of participants were genotyped using either Illumina 432 HumanOmniExpressExome-8v1 A or v1-2, and 20 032 passed QC criteria previously described.^{65,66} 433 Genotype imputation using the TOPMed reference panel was recently performed (freeze 5b) using Minimac4 434 v1.0 on the University of Michigan server https://imputationserver.sph.umich.edu.⁶⁷ Imputation data from 435 unrelated (genomic sharing identical by descent estimated using PLINK1.9 < 5%) participants were used as 436 control genotypes in a GWAS using GenOMICC cases of European ancestry, for quality check purpose of 437 associated variants. 438

439 Replication

GenOMICC EUR loci were defined by clumping function of PLINK 1.9 and clumping parameters r2 0.1 pval=5e-8 and pval2 0.01, and distance to the nearest gene was calculated using ENSEMBL grch37 gene annotation.

⁴⁴³ No GWAS has been reported of critical illness or mortality in Covid-19. As a surrogate, to provide some ⁴⁴⁴ replication for our findings, replication analyses were performed using Host Genetics Initiative build 37, ⁴⁴⁵ version 2 (July 2020) B2 (hospitalised Covid-19 vs population) v2 GWAS. Summary statistics were used from ⁴⁴⁶ the full analysis, including all cohorts and GWAS without UK Biobank, to avoid sample overlap. Replication ⁴⁴⁷ p-value was set to 0.05/n, where *n* is the number of loci significant in the discovery.

448 Post-GWAS analyses

449 **TWAS**

We performed transcriptome-wide association using the MetaXcan framework²⁵ and the GTExv8 eQTL MASHR-M models available for download (http://predictdb.org/). First GWAS results were harmonised, lifted over to hg38 and linked to 1000 Genomes reference panel using GWAS tools https://github.com/hakyi mlab/summary-gwas-imputation/wiki/GWAS-Harmonization-And-Imputation. TWAS for whole blood and lung were calculated using GWAS summary statistics for the European population GWAS and S-PrediXcan.

⁴⁵⁵ Resulting p-values were corrected using the Bonferroni correction to find significant gene associations.

456 Mendelian randomisation

Two-sample Summary data based Mendelian randomisation [PMID 27019110] was performed using the re-457 sults of GenOMICC and the Genotype-Tissue expression project, GTEx v7 (chosen in preference to v8 458 because of the availability of pre-computed data for SMR/HEIDI, [PMID 29022597] with Generation Scot-459 land [PMID 22786799; PMID 17014726] forming a linkage disequilibrium reference. GenOMICC results 460 from those of European ancestry were used as the outcome; and GTEx (v7) whole blood expression re-461 sults as the exposure. Data pertaining to GTEx v7 chosen were downloaded from the GTEx portal -462 https://gtexportal.org/ (accessed 20 Feb 2020, 05 Apr 2020, and 04 Jul 2020), and SMR/HEIDI from 463 https://cnsgenomics.com/software/smr/ (accessed 03 Jul 2020). Analyses were conducted using Python 464 3.7.3 and SMR/HEIDI v1.03. An LD reference was created using data from the population-based Genera-465 tion Scotland cohort (used with permission; described previously [PMID 28270201]): from a random set of 466 5,000 individuals, using Plink v1.9 (www.cog-genomics.org/plink/1.9/), a set of individuals with a genomic 467 relatedness cutoff < 0.01 was extracted; 2,778 individuals remained in the final set. All data used for the 468 SMR/HEIDI analyses were limited to autosomal biallelic SNPs: 4,264,462 variants remained in the final 469 merged dataset. 470

It is made available under a CC-BY-NC-ND 4.0 International license .

Significant (as per GTEx v7; nominal p-value below nominal p-value threshold) local (distance to transcriptional start site < 1Mb) eQTL from GTEx v7 whole blood for protein coding genes (as per GENCODE v19) with a MAF > 0.01 (GTEx v7 and GenOMICC) were considered as potential instrumental variables. Per variant, we first selected the Ensembl gene ID to which it was most strongly associated (so as to ensure that each variant can only be considered as an instrument for the gene to which it is most strongly associated) followed by selecting the variant to which each Ensembl gene ID was most strongly associated. Instruments were available for 4,614 unique Ensembl gene IDs.

Results were assessed based upon a list of genes selected a priori as of interest (Supplementary Table 1), 478 and together as a whole. Partial replication of Bonferroni-corrected significant results was attempted in 479 the results of COVID19-Host Genetics Initiative - https://www.covid19hg.org/ - with UK Biobank excluded 480 (accessed 21 Sep 2020). Hospitalized covid vs. population (ANA B2 V2) was selected as the phenotype 481 most similar to our own, and therefore the most appropriate for use as a replication cohort. This is not 482 a complete replication - due to the repeated use of GTEX v7 Whole Blood results in both analyses - yet 483 remains informative as to the strength of association between the genetic variant and COVID19, with a 484 consistent Mendelian Randomisation effect-size estimate. 485

486 Gene-level

⁴⁸⁷ Gene-level burden of significance in the EUR ancestry group result was calculated using MAGMA v1.08.⁶⁸

488 SNPs were annotated to genes by mapping based on genomic location. SNPs were assigned to a gene if the

489 SNPs location is within 5 kb up- or down-stream of the gene region (defined as the transcription start site

⁴⁹⁰ to transcription stop site). The MAGMA SNP-wise mean method was applied which utilises the sum of ⁴⁹¹ squared SNP Z-statistics as the test statistic. The 1000 Genomes Project European reference panel was used

⁴⁹² to estimate LD between SNPs.

⁴⁹³ Auxiliary files were downloaded from https://ctg.cncr.nl/software/magma on 1st September 2020. Gene ⁴⁹⁴ location files for protein-coding genes were obtained from NCBI (ftp.ncbi.nlm.nih.gov):

495 gene/DATA/GENE_INFO/Mammalia/Homo_sapiens.gene_info.gz

496 on 29/04/2015, and from:

genomes/Homo_sapiens/ARCHIVE/ANNOTATION_RELEASE.105/mapview/seq_gene.md.gz

498 on 25/05/2016.

⁴⁹⁹ The reference data files used to estimate LD are derived from Phase 3 of the 1000 Genomes Project.

⁵⁰⁰ Competitive gene set enrichment analysis was conducted in MAGMA using a regression model that ac ⁵⁰¹ counts for gene-gene correlations, to reduce bias resulting from clustering of functionally similar genes on the
 ⁵⁰² genome.⁶⁸ Gene sets were queried from the databases KEGG 2019, Reactome 2016, GO Biological Process
 ⁵⁰³ 2018, Biocarta 2016 and WikiPathways 2019. The Benjamini-Hochberg procedure was used to control false
 ⁵⁰⁴ discovery rate (<0.05).

⁵⁰⁵ Meta-analysis by information content (MAIC)

Multiple in vitro and in vivo studies have identified key host genes that either directly interact with SARS-506 CoV-2, or define the host response to SARS-CoV-2. We have previously reported a systematic review of 507 these studies.⁴⁵ In order to put the new associations from this GWAS into context, we performed a data-508 driven meta-analysis of gene-level results combined with pre-existing biological data using meta-analysis by 509 information content (MAIC).⁶⁹ Briefly, MAIC combines experimental results from diverse sources in the form 510 of ranked or unranked gene lists. The algorithm assigns a weighting to each input gene list, derived from the 511 degree of overlap with other input lists. Each gene is then assigned a score calculated from the weightings for 512 each gene list on which it appears. This process is repeated iteratively until all scores converge on a stable 513 value. In order to prevent a single type of experiment from unduly biasing the results, input gene lists are 514 assigned to categories, and a rule applied that only one weighting from each category can contribute to the 515 score for any given gene. 516

It is made available under a CC-BY-NC-ND 4.0 International license .

517 Tissue and functional genomic enrichment

We downloaded the mean gene expression data summarised from RNA sequencing by the GTEx project 518 (https://gtexportal.org/). The GTEx v7 data contain gene expressions of 19,791 genes in 48 human tissues. 519 Gene expression values were normalized to numbers of transcripts per million reads (TPM). To measure the 520 expression specificity of each gene in each tissue, each gene expression specificity was defined as the propor-521 tion of its expression in each tissue among all the tissues, i.e., a value ranging between 0 and 1. SNPs within 522 the 10% most specifically expressed genes in each tissue were annotated for subsequent testing of heritability 523 enrichment. For functional genomic enrichment analysis, we considered the inbuilt primary functional anno-524 tations v2.2 provided in the ldsc software (https://alkesgroup.broadinstitute.org/LDSCORE/) to annotated 525 the SNPs. 526 With the annotated SNPs, we used stratified LD score regression $(S-LDSC)^{70}$ to test whether any human 527

tissue or specific functional genomic feature is associated with serve Covid-19. Our GWAS summary statistics were harmonized by the munge_sumstats.py procedure in ldsc. LD scores of HapMap3 SNPs (MHC region excluded) for gene annotations in each tissue were computed using a 1-cM window. The enrichment score was defined as the proportion of heritability captured by the annotated SNPs divided by the proportion of SNPs annotated.

⁵³³ Testing genetic correlations with other phenotypes

We applied both the LD score regression $(LDSC)^{71}$ and high-definition likelihood $(HDL)^{26}$ methods to eval-

⁵³⁵ uate the genetic correlations between Severe Covid-19 and 818 GWASed phenotypes stored on LD-Hub.⁷²

GWAS summary statistics were harmonized by the munge_sumstats.py procedure in the ldsc software. In the HDL analysis, we estimated the SNP-based narrow-sense heritability for each phenotype, and for the 818

complex traits GWASs, those with SNPs less than 90% overlap with the HDL reference panel were removed.

539 Genome build

Results are presented using Genome Reference Consortium Human Build 37. Imputed genotypes and wholegenome sequence data were lifted over from Genome Reference Consortium Human Build 38 using Picard liftoverVCF mode from GATK 4.0 which is based on the UCSC liftover tool(chain file obtained from ftp: //ftp.ensembl.org/pub/assembly_mapping/homo_sapiens/GRCh38_to_GRCh37.chain.gz.⁷³

Acknowledgements

We thank the patients and their loved ones who volunteered to contribute to this study at one of the most difficult times in their lives, and the research staff in every intensive care unit who recruited patients at personal risk during the most extreme conditions we have ever witnessed in UK hospitals.

GenOMICC was funded by Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, 548 a Wellcome-Beit Prize award to J. K. Baillie (Wellcome Trust 103258/Z/13/A) and a BBSRC Institute 549 Program Support Grant to the Roslin Institute (BBS/E/D/20002172). Whole-genome sequencing was done 550 in partnership with Genomics England and was funded by UK Department of Health and Social Care, UKRI 551 and LifeArc. ISARIC 4C is supported by grants from: the Medical Research Council [grant MC PC 19059], 552 the National Institute for Health Research (NIHR) [award CO-CIN-01] and by the NIHR Health Protection 553 Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with 554 Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University 555 of Oxford [award 200907], NIHR HPRU in Respiratory Infections at Imperial College London with PHE 556 [award 200927], Wellcome Trust and Department for International Development [215091/Z/18/Z], and the 557 Bill and Melinda Gates Foundation [OPP1209135], and Liverpool Experimental Cancer Medicine Centre 558 (Grant Reference: C18616/A25153), NIHR Biomedical Research Centre at Imperial College London [IS-BRC-559 1215-20013], EU Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) [FP7 560 project 602525] and NIHR Clinical Research Network for providing infrastructure support for this research. 561 PJMO is supported by a NIHR Senior Investigator Award [award 201385]. The views expressed are those of 562 the authors and not necessarily those of the DHSC, DID, NIHR, MRC, Wellcome Trust or PHE. HM was 563

It is made available under a CC-BY-NC-ND 4.0 International license .

⁵⁶⁴ supported by the NIHR BRC at University College London Hospitals. The Health Research Board of Ireland
 ⁵⁶⁵ (Clinical Trial Network Award 2014-12) funds collection of samples in Ireland.

This research has been conducted using the UK Biobank Resource under project 788. Generation Scot-566 land received core support from the Chief Scientist Office of the Scottish Government Health Directorates 567 [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust 568 [216767/Z/19/Z]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at 569 the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medi-570 cal Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award STratifying Resilience 571 and Depression Longitudinally (STRADL) Reference 104036/Z/14/Z). Genomics England and the 100,000 572 Genomes Project was funded by the National Institute for Health Research, the Wellcome Trust, the Medical 573 Research Council, Cancer Research UK, the Department of Health and Social Care and NHS England. Mark 574 Caulfield is an NIHR Senior Investigator. This work is part of the portfolio of translational research at the 575 NIHR Biomedical Research Centre at Barts and Cambridge. Research performed at the Human Genetics 576 Unit was funded by the MRC (MC_UU_00007/10, MC_UU_00007/15). LK was supported by an RCUK In-577 novation Fellowship from the National Productivity Investment Fund (MR/R026408/1). ADB acknowledges 578 funding from the Wellcome Trust PhD training fellowship for clinicians (204979/Z/16/Z), the Edinburgh Clin-579 ical Academic Track (ECAT) programme. We acknowledge support from the MRC Human Genetics Unit 580 programme grant, "Quantitative traits in health and disease" (U. MC UU 00007/10). A. Tenesa acknowl-581 edges funding from the BBSRC through programme grants BBS/E/D/10002070 and BBS/E/D/30002275. 582

⁵⁸³ MRC research grant MR/P015514/1, and HDR-UK award HDR-9004 and HDR-9003.

⁵⁸⁴ This study owes a great deal to the National Institute of Healthcare Research Clinical Research Network

(NIHR CRN) and the Chief Scientist Office (Scotland), who facilitate recruitment into research studies in

⁵⁸⁶ NHS hospitals, and to the global ISARIC and InFACT consortia. We thank Dr. Jie Zheng (University of

⁵⁸⁷ Bristol) for sharing the harmonized GWAS summary statistics used in LD-Hub.

References

1.Carsana, L., Sonzogni, A., Nasr, A., Rossi, R.S., Pellegrinelli, A., Zerbi, P., Rech, R., Colombo, R., Antinori,

590 S., Corbellino, M., Galli, M., Catena, E., Tosoni, A., Gianatti, A. & Nebuloni, M. Pulmonary post-mortem

⁵⁹¹ findings in a series of covid-19 cases from northern italy: A two-centre descriptive study. *The Lancet.*

⁵⁹² Infectious diseases (2020).doi:10.1016/S1473-3099(20)30434-5

⁵⁹³ 2.Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C.,
⁵⁹⁴ Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan, C., Chappell,
⁵⁹⁵ L.C., Faust, S.N., Jaki, T., Jeffery, K., Montgomery, A., Rowan, K., Juszczak, E., Baillie, J.K., Haynes, R. &
⁵⁹⁶ Landray, M.J. Dexamethasone in hospitalized patients with covid-19 - preliminary report. *The New England*

⁵⁹⁷ *journal of medicine* (2020).doi:10.1056/NEJMoa2021436

- ⁵⁹⁸ 3.Baillie, J.K. Translational genomics. Targeting the host immune response to fight infection. *Science (New* ⁵⁹⁹ *York, N.Y.)* **344**, 807–8(2014).
- 4.Carvelli, J., Demaria, O., Vély, F., Batista, L., Benmansour, N.C., Fares, J., Carpentier, S., Thibult, M.-
- L., Morel, A., Remark, R., André, P., Represa, A., Piperoglou, C., Cordier, P.Y., Le Dault, E., Guervilly,
- 602 C., Simeone, P., Gainnier, M., Morel, Y., Ebbo, M., Schleinitz, N. & Vivier, E. Association of covid-19

inflammation with activation of the c5a-c5ar1 axis. Nature (2020).doi:10.1038/s41586-020-2600-6

- 5.Dorward, D.A., Russell, C.D., Um, I.H., Elshani, M., Armstrong, S.D., Penrice-Randal, R., Millar, T.,
- Lerpiniere, C.E., Tagliavini, G., Hartley, C.S., Randall, N.P., Gachanja, N.N., Potey, P.M., Anderson, A.M.,
- Campbell, V.L., Duguid, A.J., Qsous, W.A., BouHaidar, R., Baillie, J.K., Dhaliwal, K., Wallace, W.A.,
- ⁶⁰⁷ Bellamy, C.O., Prost, S., Smith, C., Hiscox, J.A., Harrison, D.J., Lucas, C.D. & ICECAP Tissue-specific
- tolerance in fatal Covid-19. medRxiv 2020.07.02.20145003(2020).doi:10.1101/2020.07.02.20145003
- 609 6.Sørensen, T.I., Nielsen, G.G., Andersen, P.K. & Teasdale, T.W. Genetic and environmental influences on 610 premature death in adult adoptees. *The New England journal of medicine* **318**, 727–32(1988).

It is made available under a CC-BY-NC-ND 4.0 International license .

- 7.Patarčić, I., Gelemanović, A., Kirin, M., Kolčić, I., Theodoratou, E., Baillie, K.J., Jong, M.D. de, Rudan, I.,
- 612 Campbell, H. & Polašek, O. The role of host genetic factors in respiratory tract infectious diseases: Systematic
- review, meta-analyses and field synopsis. Scientific reports 5, 16119(2015).

⁶¹⁴ 8.Horby, P., Nguyen, N.Y., Dunstan, S.J. & Baillie, J.K. An updated systematic review of the role of host ⁶¹⁵ genetics in susceptibility to influenza. *Influenza and other respiratory viruses* **7** Suppl **2**, 37–41(2013).

9.Clohisey, S. & Baillie, J.K. Host susceptibility to severe influenza A virus infection. *Critical Care* 23, 303(2019).

10.Shelton, J.F., Shastri, A.J., Ye, C., Weldon, C.H., Filshtein-Somnez, T., Coker, D., Symons,
A., Esparza-Gordillo, J., Team, T.2.C.-1., Aslibekyan, S. & Auton, A. Trans-ethnic analysis reveals genetic and non-genetic associations with COVID-19 susceptibility and severity. *medRxiv*2020.09.04.20188318(2020).doi:10.1101/2020.09.04.20188318

11.Ellinghaus, D., Degenhardt, F., Bujanda, L., Buti, M., Albillos, A., Invernizzi, P., Fernández, J., Prati,

D., Baselli, G., Asselta, R., Grimsrud, M.M., Milani, C., Aziz, F., Kässens, J., May, S., Wendorff, M.,

- Wienbrandt, L., Uellendahl-Werth, F., Zheng, T., Yi, X., Pablo, R. de, Chercoles, A.G., Palom, A., Garcia-
- ⁶²⁵ Fernandez, A.-E., Rodriguez-Frias, F., Zanella, A., Bandera, A., Protti, A., Aghemo, A., Lleo, A., Biondi,
- A., Caballero-Garralda, A., Gori, A., Tanck, A., Carreras Nolla, A., Latiano, A., Fracanzani, A.L., Peschuck,
- ⁶²⁷ A., Julià, A., Pesenti, A., Voza, A., Jiménez, D., Mateos, B., Nafria Jimenez, B., Quereda, C., Paccapelo, ⁶²⁸ C., Gassner, C., Angelini, C., Cea, C., Solier, A., Pestaña, D., Muñiz-Diaz, E., Sandoval, E., Paraboschi,
- E.M., Navas, E., García Sánchez, F., Ceriotti, F., Martinelli-Boneschi, F., Peyvandi, F., Blasi, F., Téllez,
- L., Blanco-Grau, A., Hemmrich-Stanisak, G., Grasselli, G., Costantino, G., Cardamone, G., Foti, G., Aneli,
- 631 S., Kurihara, H., ElAbd, H., My, I., Galván-Femenia, I., Martín, J., Erdmann, J., Ferrusquía-Acosta, J.,
- Garcia-Etxebarria, K., Izquierdo-Sanchez, L., Bettini, L.R., Sumoy, L., Terranova, L., Moreira, L., Santoro,
- L., Scudeller, L., Mesonero, F., Roade, L., Rühlemann, M.C., Schaefer, M., Carrabba, M., Riveiro-Barciela,
- ⁶³⁴ M., Figuera Basso, M.E., Valsecchi, M.G., Hernandez-Tejero, M., Acosta-Herrera, M., D'Angiò, M., Baldini,
- M., Cazzaniga, M., Schulzky, M., Cecconi, M., Wittig, M., Ciccarelli, M., Rodríguez-Gandía, M., Bocciolone,
- M., Miozzo, M., Montano, N., Braun, N., Sacchi, N., Martínez, N., Özer, O., Palmieri, O., Faverio, P.,
- Preatoni, P., Bonfanti, P., Omodei, P., Tentorio, P., Castro, P., Rodrigues, P.M., Blandino Ortiz, A., Cid,
 R. de, Ferrer, R., Gualtierotti, R., Nieto, R., Goerg, S., Badalamenti, S., Marsal, S., Matullo, G., Pelusi,
- ⁶³⁸ R. de, Ferrer, R., Gualtierotti, R., Nieto, R., Goerg, S., Badalamenti, S., Marsal, S., Matullo, G., Pelusi, ⁶³⁹ S., Juzenas, S., Aliberti, S., Monzani, V., Moreno, V., Wesse, T., Lenz, T.L., Pumarola, T., Rimoldi, V.,
- Bosari, S., Albrecht, W., Peter, W., Romero-Gómez, M., D'Amato, M., Duga, S., Banales, J.M., Hov, J.R.,
- ⁶⁴¹ Folseraas, T., Valenti, L., Franke, A. & Karlsen, T.H. Genomewide association study of severe covid-19 with
- respiratory failure. The New England journal of medicine (2020).doi:10.1056/NEJMoa2020283

⁶⁴³ 12.Casanova, J.-L. Severe infectious diseases of childhood as monogenic inborn errors of immunity. *Proceed-*⁶⁴⁴ *ings of the National Academy of Sciences of the United States of America* **112**, E7128–37(2015).

- ⁶⁴⁵ 13.Plenge, R.M. Molecular underpinnings of severe coronavirus disease 2019. JAMA (2020).doi:10.1001/jama.2020.14015
- 14.Millar, J.E., Neyton, L., Seth, S., Dunning, J., Merson, L., Murthy, S., Russell, C.D., Keating, S., Swets,
- 647 M., Sudre, C.H., Spector, T.D., Ourselin, S., Steves, C.J., Wolf, J., Investigators, I., Docherty, A.B., Harrison,
- E.M., Openshaw, P.J., Semple, M.G. & Baillie, J.K. Robust, reproducible clinical patterns in hospitalised
- 649 patients with COVID-19. medRxiv 2020.08.14.20168088(2020).doi:10.1101/2020.08.14.20168088
- ⁶⁵⁰ 15.Docherty, A.B., Harrison, E.M., Green, C.A., Hardwick, H.E., Pius, R., Norman, L., Holden, K.A., Read,
- J.M., Dondelinger, F., Carson, G., Merson, L., Lee, J., Plotkin, D., Sigfrid, L., Halpin, S., Jackson, C.,
- Gamble, C., Horby, P.W., Nguyen-Van-Tam, J.S., Ho, A., Russell, C.D., Dunning, J., Openshaw, P.J.,
- Baillie, J.K. & Semple, M.G. Features of 200.167em133 uk patients in hospital with covid-19 using the isaric
- ⁶⁵⁴ who clinical characterisation protocol: Prospective observational cohort study. BMJ (Clinical research ed.)
- $\mathbf{655}$ **369**, m1985(2020).
- 16.Angus, D.C., Derde, L., Al-Beidh, F., Annane, D., Arabi, Y., Beane, A., Bentum-Puijk, W. van, Berry,
- L., Bhimani, Z., Bonten, M., Bradbury, C., Brunkhorst, F., Buxton, M., Buzgau, A., Cheng, A.C., Jong, M.
- de, Detry, M., Estcourt, L., Fitzgerald, M., Goossens, H., Green, C., Haniffa, R., Higgins, A.M., Horvat, C.,
- Hullegie, S.J., Kruger, P., Lamontagne, F., Lawler, P.R., Linstrum, K., Litton, E., Lorenzi, E., Marshall, J.,
- McAuley, D., McGlothin, A., McGuinness, S., McVerry, B., Montgomery, S., Mouncey, P., Murthy, S., Nichol,

- A., Parke, R., Parker, J., Rowan, K., Sanil, A., Santos, M., Saunders, C., Seymour, C., Turner, A., Veerdonk,
- ⁶⁶² F. van de, Venkatesh, B., Zarychanski, R., Berry, S., Lewis, R.J., McArthur, C., Webb, S.A. & Gordon, A.C.
- Effect of hydrocortisone on mortality and organ support in patients with severe covid-19: The remap-cap
- $_{664}$ covid-19 corticosteroid domain randomized clinical trial. JAMA (2020).doi:10.1001/jama.2020.17022
- ⁶⁶⁵ 17.Baillie, J.K. & Digard, P. Influenza Time to Target the Host? New England Journal of Medicine **369**, ⁶⁶⁶ 191–193(2013).
- 667 18.D, T., Dn, H., Md, K., J, C., Za, S., R, T., Sag, T., A, C., Sm, G., Hm, K., An, P., J, L., S, L., X, T.,
- ⁶⁶⁸ Bl, B., S, D., A, E., We, C., Dp, L., Ac, S., Tw, B., Q, W., Dk, A., Ae, A.-K., Kc, B., E, B., S, G., R, G.,
- 669 Km, R., Ss, R., E, S., P, Q., W, G., Gj, P., Da, N., Sr, B., Mc, Z., S, Z., Jg, W., La, C., Cc, L., Ce, J., Rd,
- H., Td, O., Gr, A. & undefined Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
- 671 (2019).doi:10.1101/563866
- 19. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P., Boehnke, M., Abecasis,
- G.R. & Willer, C.J. LocusZoom: Regional visualization of genome-wide association scan results. *Bioinfor-*
- 674 matics (Oxford, England) **26**, 2336–7(2010).
- ⁶⁷⁵ 20.Willer, C.J., Li, Y. & Abecasis, G.R. METAL: Fast and efficient meta-analysis of genomewide association ⁶⁷⁶ scans. *Bioinformatics (Oxford, England)* **26**, 2190–1(2010).
- 677 21.Bretherick, A.D., Canela-Xandri, O., Joshi, P.K., Clark, D.W., Rawlik, K., Boutin, T.S., Zeng, Y.,
- Amador, C., Navarro, P., Rudan, I., Wright, A.F., Campbell, H., Vitart, V., Hayward, C., Wilson, J.F.,
- ⁶⁷⁹ Tenesa, A., Ponting, C.P., Baillie, J.K. & Haley, C. Linking protein to phenotype with mendelian randomiza-
- tion detects 38 proteins with causal roles in human diseases and traits. *PLoS genetics* **16**, e1008785(2020).
- ⁶⁸¹ 22.Zhu, Z., Zhang, F., Hu, H., Bakshi, A., Robinson, M.R., Powell, J.E., Montgomery, G.W., Goddard, M.E.,
 ⁶⁸² Wray, N.R., Visscher, P.M. & Yang, J. Integration of summary data from gwas and eQTL studies predicts
- ⁶⁸³ complex trait gene targets. Nature genetics 48, 481–7(2016).
- 23.Gamazon, E.R., Wheeler, H.E., Shah, K.P., Mozaffari, S.V., Aquino-Michaels, K., Carroll, R.J., Eyler,
- A.E., Denny, J.C., Nicolae, D.L., Cox, N.J. & Im, H.K. A gene-based association method for mapping traits
- ⁶⁸⁶ using reference transcriptome data. Nature genetics 47, 1091–8(2015).
- 24.Gusev, A., Ko, A., Shi, H., Bhatia, G., Chung, W., Penninx, B.W.J.H., Jansen, R., Geus, E.J.C. de,
- Boomsma, D.I., Wright, F.A., Sullivan, P.F., Nikkola, E., Alvarez, M., Civelek, M., Lusis, A.J., Lehtimäki, T.,
- Raitoharju, E., Kähönen, M., Seppälä, I., Raitakari, O.T., Kuusisto, J., Laakso, M., Price, A.L., Pajukanta, P.
- ⁶⁹⁰ & Pasaniuc, B. Integrative approaches for large-scale transcriptome-wide association studies. *Nature genetics* ⁶⁹¹ **48**, 245–52(2016).
- ⁶⁹² 25.Barbeira, A.N., Dickinson, S.P., Bonazzola, R., Zheng, J., Wheeler, H.E., Torres, J.M., Torstenson, E.S.,
- Shah, K.P., Garcia, T., Edwards, T.L., Stahl, E.A., Huckins, L.M., Nicolae, D.L., Cox, N.J. & Im, H.K. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from gwas summary
 statistics. Nature communications 9, 1825(2018).
- ⁶⁹⁶ 26.Ning, Z., Pawitan, Y. & Shen, X. High-definition likelihood inference of genetic correlations across human
 ⁶⁹⁷ complex traits. *Nature genetics* 52, 859–864(2020).
- ⁶⁹⁸ 27.Andersson, R., Gebhard, C., Miguel-Escalada, I., Hoof, I., Bornholdt, J., Boyd, M., Chen, Y., Zhao, X.,
- Schmidl, C., Suzuki, T., Ntini, E., Arner, E., Valen, E., Li, K., Schwarzfischer, L., Glatz, D., Raithel, J.,
- Lilje, B., Rapin, N., Bagger, F.O., Jørgensen, M., Andersen, P.R., Bertin, N., Rackham, O., Burroughs, A.M.,
- Baillie, J.K., Ishizu, Y., Shimizu, Y., Furuhata, E., Maeda, S., Negishi, Y., Mungall, C.J., Meehan, T.F.,
- Lassmann, T., Itoh, M., Kawaji, H., Kondo, N., Kawai, J., Lennartsson, A., Daub, C.O., Heutink, P., Hume,
- 703 D.A., Jensen, T.H., Suzuki, H., Hayashizaki, Y., Müller, F., Consortium, T.F., Forrest, A.R.R., Carninci,
- P., Rehli, M. & Sandelin, A. An atlas of active enhancers across human cell types and tissues. Nature 507, 455–461(2014).
- 28.Villar, D., Berthelot, C., Aldridge, S., Rayner, T.F., Lukk, M., Pignatelli, M., Park, T.J., Deaville, R.,
 Erichsen, J.T., Jasinska, A.J., Turner, J.M.A., Bertelsen, M.F., Murchison, E.P., Flicek, P. & Odom, D.T.
- ⁷⁰⁸ Enhancer evolution across 20 mammalian species. *Cell* **160**, 554–66(2015).

- ⁷⁰⁹ 29.Plenge, R.M., Scolnick, E.M. & Altshuler, D. Validating therapeutic targets through human genetics.
 ⁷¹⁰ Nature Reviews Drug Discovery 12, 581–594(2013).
- ⁷¹¹ 30.Davies, N.M., Holmes, M.V. & Smith, G.D. Reading Mendelian randomisation studies: A guide, glossary, ⁷¹² and checklist for clinicians. *BMJ* **362**, k601(2018).
- ⁷¹³ 31.Wunsch, H., Linde-Zwirble, W.T., Angus, D.C., Hartman, M.E., Milbrandt, E.B. & Kahn, J.M. The ⁷¹⁴ epidemiology of mechanical ventilation use in the united states. *Critical care medicine* **38**, 1947–53(2010).
- ⁷¹⁵ 32.Sadler, A.J. & Williams, B.R.G. Interferon-inducible antiviral effectors. Nature reviews. Immunology 8,
 ⁷¹⁶ 559–68(2008).
- 33.Duncan, C.J.A., Mohamad, S.M.B., Young, D.F., Skelton, A.J., Leahy, T.R., Munday, D.C., Butler, K.M.,
- ⁷¹⁸ Morfopoulou, S., Brown, J.R., Hubank, M., Connell, J., Gavin, P.J., McMahon, C., Dempsey, E., Lynch, N.E.,
- ⁷¹⁹ Jacques, T.S., Valappil, M., Cant, A.J., Breuer, J., Engelhardt, K.R., Randall, R.E. & Hambleton, S. Human
- ⁷²⁰ ifnar2 deficiency: Lessons for antiviral immunity. *Science translational medicine* **7**, 307ra154(2015).
- ⁷²¹ 34.Hambleton, S., Goodbourn, S., Young, D.F., Dickinson, P., Mohamad, S.M.B., Valappil, M., McGovern,
- N., Cant, A.J., Hackett, S.J., Ghazal, P., Morgan, N.V. & Randall, R.E. STAT2 deficiency and susceptibility
- ⁷²³ to viral illness in humans. Proceedings of the National Academy of Sciences of the United States of America
- 724 **110**, 3053-8(2013).
- 35.Shepardson, K.M., Larson, K., Johns, L.L., Stanek, K., Cho, H., Wellham, J., Henderson, H. & Rynda-
- ⁷²⁶ Apple, A. IFNAR2 is required for anti-influenza immunity and alters susceptibility to post-influenza bacterial
- ⁷²⁷ superinfections. Frontiers in immunology 9, 2589(2018).
- ⁷²⁸ 36.Choi, U.Y., Kang, J.-S., Hwang, Y.S. & Kim, Y.-J. Oligoadenylate synthase-like (oasl) proteins: Dual ⁷²⁹ functions and associations with diseases. *Experimental & molecular medicine* **47**, e144(2015).
- ⁷³⁰ 37.Hagemeijer, M.C., Vonk, A.M., Monastyrska, I., Rottier, P.J.M. & Haan, C.A.M. de Visualizing coron-⁷³¹ avirus rna synthesis in time by using click chemistry. *Journal of virology* **86**, 5808–16(2012).
- 732 38.Hamano, E., Hijikata, M., Itoyama, S., Quy, T., Phi, N.C., Long, H.T., Ha, L.D., Ban, V.V., Matsushita,
- ⁷³³ I., Yanai, H., Kirikae, F., Kirikae, T., Kuratsuji, T., Sasazuki, T. & Keicho, N. Polymorphisms of interferon-
- inducible genes oas-1 and mxa associated with sars in the vietnamese population. *Biochemical and biophysical research communications* **329**, 1234–9(2005).
- ⁷³⁶ 39.He, J., Feng, D., Vlas, S.J. de, Wang, H., Fontanet, A., Zhang, P., Plancoulaine, S., Tang, F., Zhan, L.,
 ⁷³⁷ Yang, H., Wang, T., Richardus, J.H., Habbema, J.D.F. & Cao, W. Association of sars susceptibility with
 ⁷³⁸ single nucleic acid polymorphisms of oas1 and mxa genes: A case-control study. *BMC infectious diseases* 6,
 ⁷³⁹ 106(2006).
- 40.Fingerlin, T.E., Murphy, E., Zhang, W., Peljto, A.L., Brown, K.K., Steele, M.P., Loyd, J.E., Cosgrove, 740 G.P., Lynch, D., Groshong, S., Collard, H.R., Wolters, P.J., Bradford, W.Z., Kossen, K., Seiwert, S.D., Bois, 741 R.M. du, Garcia, C.K., Devine, M.S., Gudmundsson, G., Isaksson, H.J., Kaminski, N., Zhang, Y., Gibson, 742 K.F., Lancaster, L.H., Cogan, J.D., Mason, W.R., Maher, T.M., Molyneaux, P.L., Wells, A.U., Moffatt, 743 M.F., Selman, M., Pardo, A., Kim, D.S., Crapo, J.D., Make, B.J., Regan, E.A., Walek, D.S., Daniel, J.J., 744 Kamatani, Y., Zelenika, D., Smith, K., McKean, D., Pedersen, B.S., Talbert, J., Kidd, R.N., Markin, C.R., 745 Beckman, K.B., Lathrop, M., Schwarz, M.I. & Schwartz, D.A. Genome-wide association study identifies 746 multiple susceptibility loci for pulmonary fibrosis. Nature genetics 45, 613–20(2013). 747
- 41.Allen, R.J., Guillen-Guio, B., Oldham, J.M., Ma, S.-F., Dressen, A., Paynton, M.L., Kraven, L.M., Obeidat, M., Li, X., Ng, M., Braybrooke, R., Molina-Molina, M., Hobbs, B.D., Putman, R.K., Sakornsakolpat,
 P., Booth, H.L., Fahy, W.A., Hart, S.P., Hill, M.R., Hirani, N., Hubbard, R.B., McAnulty, R.J., Millar,
 A.B., Navaratnam, V., Oballa, E., Parfrey, H., Saini, G., Whyte, M.K.B., Zhang, Y., Kaminski, N., Adegunsoye, A., Strek, M.E., Neighbors, M., Sheng, X.R., Gudmundsson, G., Gudnason, V., Hatabu, H., Lederer,
 D.J., Manichaikul, A., Newell, J.D., O'Connor, G.T., Ortega, V.E., Xu, H., Fingerlin, T.E., Bossé, Y., Hao,
 K., Joubert, P., Nickle, D.C., Sin, D.D., Timens, W., Furniss, D., Morris, A.P., Zondervan, K.T., Hall,
- ⁷⁵⁵ I.P., Sayers, I., Tobin, M.D., Maher, T.M., Cho, M.H., Hunninghake, G.M., Schwartz, D.A., Yaspan, B.L.,

- Molyneaux, P.L., Flores, C., Noth, I., Jenkins, R.G. & Wain, L.V. Genome-wide association study of sus-
- ⁷⁵⁷ ceptibility to idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 201,
 ⁷⁵⁸ 564–574(2020).
- 42.Zhang, H., Maqsudi, S., Rainczuk, A., Duffield, N., Lawrence, J., Keane, F.M., Justa-Schuch, D., Geiss Friedlander, R., Gorrell, M.D. & Stephens, A.N. Identification of novel dipeptidyl peptidase 9 substrates by
 two-dimensional differential in-gel electrophoresis. *The FEBS journal* 282, 3737–57(2015).
- 43.Geiss-Friedlander, R., Parmentier, N., Möller, U., Urlaub, H., Van den Eynde, B.J. & Melchior, F. The
 cytoplasmic peptidase dpp9 is rate-limiting for degradation of proline-containing peptides. *The Journal of biological chemistry* 284, 27211–9(2009).
- 44.Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J.,
 Jensen, L.J., Karlsson, A., Liu, G., Ma'ayan, A., Mandava, G., Mani, S., Mehta, S., Overington, J., Patel,
 J., Rouillard, A.D., Schürer, S., Sheils, T., Simeonov, A., Sklar, L.A., Southall, N., Ursu, O., Vidovic, D.,
 Waller, A., Yang, J., Jadhav, A., Oprea, T.I. & Guha, R. Pharos: Collating protein information to shed light
 on the druggable genome. *Nucleic acids research* 45, D995–D1002(2017).
- 45.Parkinson, N., Rodgers, N., Fourman, M.H., Wang, B., Zechner, M., Swets, M., Millar, J.E., Law, A., Russell, C., Baillie, J.K. & Clohisey, S. Systematic review and meta-analysis identifies potential host therapeutic targets in COVID-19. *medRxiv* 2020.08.27.20182238(2020).doi:10.1101/2020.08.27.20182238
- 46.Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., Yang, D.,
- 774 Zhang, G., Li, H., Chen, F., Xu, Y., Chen, M., Gao, Z., Yang, J., Dong, J., Liu, B., Zhang, X., Wang, W.,
- He, K., Jin, Q., Li, M. & Wang, J. Heightened innate immune responses in the respiratory tract of covid-19
- 776 patients. Cell host & microbe 27, 883–890.e2(2020).
- 47.Zhao, Y., Qin, L., Zhang, P., Li, K., Liang, L., Sun, J., Xu, B., Dai, Y., Li, X., Zhang, C., Peng, Y., Feng,
- 778 Y., Li, A., Hu, Z., Xiang, H., Ogg, G., Ho, L.-P., McMichael, A., Jin, R., Knight, J.C., Dong, T. & Zhang, Y.
- ⁷⁷⁹ Longitudinal covid-19 profiling associates il-1RA and il-10 with disease severity and rantes with mild disease.
- ⁷⁸⁰ JCI insight **5**, (2020).
- 48.Vergunst, C.E., Gerlag, D.M., Lopatinskaya, L., Klareskog, L., Smith, M.D., Bosch, F. van den, Dinant,
 H.J., Lee, Y., Wyant, T., Jacobson, E.W., Baeten, D. & Tak, P.P. Modulation of ccr2 in rheumatoid arthritis:
 A double-blind, randomized, placebo-controlled clinical trial. Arthritis and rheumatism 58, 1931–9(2008).
- 49.Docherty, A.B., Harrison, E.M., Green, C.A., Hardwick, H.E., Pius, R., Norman, L., Holden, K.A., Read,
- J.M., Dondelinger, F., Carson, G., Merson, L., Lee, J., Plotkin, D., Sigfrid, L., Halpin, S., Jackson, C.,
- Gamble, C., Horby, P.W., Nguyen-Van-Tam, J.S., Ho, A., Russell, C.D., Dunning, J., Openshaw, P.J.,
 Baillie, J.K. & Semple, M.G. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC
- ⁷⁸⁷ Baillie, J.K. & Semple, M.G. Features of 20 133 UK patients in hospital with covid-19 using the L ⁷⁸⁸ WHO Clinical Characterisation Protocol: Prospective observational cohort study. *BMJ* **369**, (2020).
- ⁷⁸⁹ 50.Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., Curtis, H.J., Mehrkar,
 ⁷⁹⁰ A., Evans, D., Inglesby, P., Cockburn, J., McDonald, H.I., MacKenna, B., Tomlinson, L., Douglas, I.J.,
 ⁷⁹¹ Rentsch, C.T., Mathur, R., Wong, A.Y.S., Grieve, R., Harrison, D., Forbes, H., Schultze, A., Croker, R.,
 ⁷⁹² Parry, J., Hester, F., Harper, S., Perera, R., Evans, S.J.W., Smeeth, L. & Goldacre, B. Factors associated
- Parry, J., Hester, F., Harper, S., Perera, R., Evans, S.J.W., Smeeth, L. & Goldacre, B. Factors associate
 with covid-19-related death using opensafely. *Nature* 584, 430–436(2020).
- 51.Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J.,
- Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J., Silman, A., Young, A., Sprosen, T., Peakman, T. &
- ⁷⁹⁶ Collins, R. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex
- ⁷⁹⁷ Diseases of Middle and Old Age. *PLOS Medicine* **12**, e1001779(2015).
- ⁷⁹⁸ 52.McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Alt-⁷⁹⁹ shuler, D., Gabriel, S., Daly, M. & DePristo, M.A. The genome analysis toolkit: A mapreduce framework for ⁸⁰⁰ analyzing next-generation dna sequencing data. *Genome research* **20**, 1297–303(2010).
- ⁸⁰¹ 53.Meynert, A.M., Ansari, M., FitzPatrick, D.R. & Taylor, M.S. Variant detection sensitivity and biases in ⁸⁰² whole genome and exome sequencing. *BMC bioinformatics* **15**, 247(2014).

- ⁸⁰³ 54.Guo, Y., He, J., Zhao, S., Wu, H., Zhong, X., Sheng, Q., Samuels, D.C., Shyr, Y. & Long, J. Illumina ⁸⁰⁴ human exome genotyping array clustering and quality control. *Nature protocols* **9**, 2643–62(2014).
- 55.Gaziano, J.M., Concato, J., Brophy, M., Fiore, L., Pyarajan, S., Breeling, J., Whitbourne, S., Deen, J.,
- Shannon, C., Humphries, D., Guarino, P., Aslan, M., Anderson, D., LaFleur, R., Hammond, T., Schaa, K.,
- Moser, J., Huang, G., Muralidhar, S., Przygodzki, R. & O'Leary, T.J. Million veteran program: A mega-
- ⁸⁰⁸ biobank to study genetic influences on health and disease. Journal of clinical epidemiology 70, 214–23(2016).
- 56.Manichaikul, A., Mychaleckyj, J.C., Rich, S.S., Daly, K., Sale, M. & Chen, W.-M. Robust relationship inference in genome-wide association studies. *Bioinformatics (Oxford, England)* **26**, 2867–73(2010).
- ⁸¹¹ 57.Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: A tool for genome-wide complex trait analysis. ⁸¹² American journal of human genetics **88**, 76–82(2011).
- ⁸¹³ 58.Alexander, D.H. & Lange, K. Enhancements to the admixture algorithm for individual ancestry estimation. ⁸¹⁴ *BMC bioinformatics* **12**, 246(2011).
- ⁸¹⁵ 59.Wigginton, J.E., Cutler, D.J. & Abecasis, G.R. A note on exact tests of hardy-weinberg equilibrium. ⁸¹⁶ American journal of human genetics **76**, 887–93(2005).
- 60.Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M. & Lee, J.J. Second-generation plink: Rising to the challenge of larger and richer datasets. *GigaScience* 4, 7(2015).
- 61. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: Principal component analysis of biobank-scale genotype datasets. *Bioinformatics (Oxford, England)* **33**, 2776–2778(2017).
- 62.Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins, R.L., Laricchia,
- K.M., Ganna, A., Birnbaum, D.P., Gauthier, L.D., Brand, H., Solomonson, M., Watts, N.A., Rhodes, D.,
- Singer-Berk, M., England, E.M., Seaby, E.G., Kosmicki, J.A., Walters, R.K., Tashman, K., Farjoun, Y.,
- Banks, E., Poterba, T., Wang, A., Seed, C., Whiffin, N., Chong, J.X., Samocha, K.E., Pierce-Hoffman, E.,
- Zappala, Z., O'Donnell-Luria, A.H., Minikel, E.V., Weisburd, B., Lek, M., Ware, J.S., Vittal, C., Armean,
- I.M., Bergelson, L., Cibulskis, K., Connolly, K.M., Covarrubias, M., Donnelly, S., Ferriera, S., Gabriel, S.,
- Gentry, J., Gupta, N., Jeandet, T., Kaplan, D., Llanwarne, C., Munshi, R., Novod, S., Petrillo, N., Roazen,
- D., Ruano-Rubio, V., Saltzman, A., Schleicher, M., Soto, J., Tibbetts, K., Tolonen, C., Wade, G., Talkowski,
- M.E., Neale, B.M., Daly, M.J. & MacArthur, D.G. The mutational constraint spectrum quantified from
- variation in 141,456 humans. *Nature* **581**, 434–443(2020).
- 63.Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., Bender, D., Maller, J., Sklar, P., Bakker, P.I.W. de, Daly, M.J. & Sham, P.C. PLINK: A tool set for whole-genome association and populationbased linkage analyses. *American journal of human genetics* **81**, 559–75(2007).
- 64.Smith, B.H., Campbell, A., Linksted, P., Fitzpatrick, B., Jackson, C., Kerr, S.M., Deary, I.J., Macintyre,
- D.J., Campbell, H., McGilchrist, M., Hocking, L.J., Wisely, L., Ford, I., Lindsay, R.S., Morton, R., Palmer,
- C.N.A., Dominiczak, A.F., Porteous, D.J. & Morris, A.D. Cohort profile: Generation scotland: Scottish
- family health study (gs:SFHS). The study, its participants and their potential for genetic research on health
- and illness. International journal of epidemiology 42, 689-700(2013).
- 65.Amador, C., Huffman, J., Trochet, H., Campbell, A., Porteous, D., Wilson, J.F., Hastie, N., Vitart, V.,
 Hayward, C., Navarro, P. & Haley, C.S. Recent genomic heritage in scotland. *BMC genomics* 16, 437(2015).
- 66.Nagy, R., Boutin, T.S., Marten, J., Huffman, J.E., Kerr, S.M., Campbell, A., Evenden, L., Gibson, J.,
- Amador, C., Howard, D.M., Navarro, P., Morris, A., Deary, I.J., Hocking, L.J., Padmanabhan, S., Smith,
- B.H., Joshi, P., Wilson, J.F., Hastie, N.D., Wright, A.F., McIntosh, A.M., Porteous, D.J., Haley, C.S., Vitart,
- ⁸⁴⁴ V. & Hayward, C. Exploration of haplotype research consortium imputation for genome-wide association
- studies in 20,032 generation scotland participants. Genome medicine 9, 23(2017).
- 67.Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, S.I., Chew, E.Y., Levy, S.,
- McGue, M., Schlessinger, D., Stambolian, D., Loh, P.-R., Iacono, W.G., Swaroop, A., Scott, L.J., Cucca,
- ⁸⁴⁸ F., Kronenberg, F., Boehnke, M., Abecasis, G.R. & Fuchsberger, C. Next-generation genotype imputation
- ⁸⁴⁹ service and methods. *Nature genetics* **48**, 1284–1287(2016).

- 68.Leeuw, C.A. de, Mooij, J.M., Heskes, T. & Posthuma, D. MAGMA: Generalized gene-set analysis of gwas 850 data. *PLoS computational biology* **11**, e1004219(2015). 851
- 69.Li, B., Clohisey, S.M., Chia, B.S., Wang, B., Cui, A., Eisenhaure, T., Schweitzer, L.D., Hoover, P., 852
- Parkinson, N.J., Nachshon, A., Smith, N., Regan, T., Farr, D., Gutmann, M.U., Bukhari, S.I., Law, A., 853
- Sangesland, M., Gat-Viks, I., Digard, P., Vasudevan, S., Lingwood, D., Dockrell, D.H., Doench, J.G., Baillie, 854
- J.K. & Hacohen, N. Genome-wide CRISPR screen identifies host dependency factors for influenza A virus 855
- infection. Nature Communications 11, 164(2020). 856
- 70.Finucane, H.K., Bulik-Sullivan, B., Gusev, A., Trynka, G., Reshef, Y., Loh, P.-R., Anttila, V., Xu, 857 H., Zang, C., Farh, K., Ripke, S., Day, F.R., Purcell, S., Stahl, E., Lindstrom, S., Perry, J.R.B., Okada, Y., 858 Raychaudhuri, S., Daly, M.J., Patterson, N., Neale, B.M. & Price, A.L. Partitioning heritability by functional 859
- annotation using genome-wide association summary statistics. Nature genetics 47, 1228–35(2015). 860
- 71.Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.-R., Duncan, L., Perry, 861
- J.R.B., Patterson, N., Robinson, E.B., Daly, M.J., Price, A.L. & Neale, B.M. An atlas of genetic correlations 862
- across human diseases and traits. Nature genetics 47, 1236–41(2015). 863
- 72.Zheng, J., Erzurumluoglu, A.M., Elsworth, B.L., Kemp, J.P., Howe, L., Haycock, P.C., Hemani, G., 864
- Tansey, K., Laurin, C., Pourcain, B.S., Warrington, N.M., Finucane, H.K., Price, A.L., Bulik-Sullivan, B.K., 865
- Anttila, V., Paternoster, L., Gaunt, T.R., Evans, D.M. & Neale, B.M. LD hub: A centralized database and 866
- web interface to perform ld score regression that maximizes the potential of summary level gwas data for snp 867
- heritability and genetic correlation analysis. *Bioinformatics (Oxford, England)* **33**, 272–279(2017). 868
- 73. Hinrichs, A.S., Karolchik, D., Baertsch, R., Barber, G.P., Bejerano, G., Clawson, H., Diekhans, M., 869
- Furey, T.S., Harte, R.A., Hsu, F., Hillman-Jackson, J., Kuhn, R.M., Pedersen, J.S., Pohl, A., Raney, B.J., 870 Rosenbloom, K.R., Siepel, A., Smith, K.E., Sugnet, C.W., Sultan-Qurraie, A., Thomas, D.J., Trumbower,
- 871 H., Weber, R.J., Weirauch, M., Zweig, A.S., Haussler, D. & Kent, W.J. The ucsc genome browser database:
- 872
- Update 2006. Nucleic acids research 34, D590-8(2006). 873